[Thrombophilia and fetal loss syndrome]

Pathological states associated with congenital and acquired hemostasis defects remain a pressing problem of practical obstetrics. Thrombophilia is responsible for 30-50% of habitual miscarriages, severe gestosis, detachment of normally attached placenta, preterm delivery, etc. Therefore, today correct therapeutic strategy determines the prevention of reproductive loss caused by thrombophilic state. A complex of studies aimed at drug prevention of miscarriages has been performed at Department of Obstetrics and Gynecology, Medical Prophylaxis Faculty of I. M. Setchenov Moscow Medical Academy. Seventy-two pregnant women without extragenital diseases with verified congenital or acquired hemophilia and fetal loss syndrome were observed. Various therapeutic protocols with low-molecular-weight heparin were used. Positive clinical results were attained: no relapses of thrombosis and fetal loss occurred in the majority of cases, though the incidence of preterm labor and placental insufficiency remained high.